Marie Dutreix YOU? Author Swipe

Last 10y

Sparing effects of FLASH irradiation in patient-derived lung tissue Open

Maxime Dubail, Chloé Lafouasse, Sophie Heinrich, Vincent Favaudon, Arturo Londoño‐Vallejo , et al. · 2025

The AsiDNA™ decoy mimicking DSBs protects the normal tissue from radiation toxicity through a DNA-PK/p53/p21-dependent G1/S arrest Open

Anouk Sesink, Margaux Becerra, Jia-Ling Ruan, Sophie Leboucher, Maxime Dubail , et al. · 2024

AsiDNA™, a cholesterol-coupled oligonucleotide mimicking double-stranded DNA breaks, was developed to sensitize tumour cells to radio- and chemotherapy. This drug acts as a decoy hijacking the DNA damage response. Previous studies have dem…

Lung Organotypic Slices Enable Rapid Quantification of Acute Radiotherapy Induced Toxicity Open

Maxime Dubail, Sophie Heinrich, Lucie Portier, Jessica Bastian, Lucia Giuliano , et al. · 2023

To rapidly assess healthy tissue toxicities induced by new anti-cancer therapies (i.e., radiation alone or in combination with drugs), there is a critical need for relevant and easy-to-use models. Consistent with the ethical desire to redu…

An interactive murine single-cell atlas of the lung responses to radiation injury Open

Sandra Curras-Alonso, Juliette Soulier, Thomas Defard, Christian Weber, Sophie Heinrich , et al. · 2023

Radiation Induced Lung Injury (RILI) is one of the main limiting factors of thorax irradiation, which can induce acute pneumonitis as well as pulmonary fibrosis, the latter being a life-threatening condition. The order of cellular and mole…

Sup Figure S2 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Sup Figure S2.AsiDNA does not induce cell cycle modification: Normal and malignant cells were analyzed by flow cytometry after 12, 24 and 48 hours of treatment with 4.8 Ãƒâ€šÃ,âµM AsiDNA. Results are expressed as the mean of the percentage…

Sup Figure S1 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Sup Figure S1. AsiDNA Structure and Cell survival in response to AsiDNA treatment. (A) AsiDNA structure: AsiDNA is the clinical form of Dbait, a 64-nucleotide (nt) oligodeoxyribonucleotide consisting of two complementary 32-nt strands, con…

Sup Figure S8 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Sup Figure S8. Time course analysis of pDC activation by CpG- Dbait. Representative experiments of time course analysis of pDC activation by flow cytometry analysis of cell membrane activation markers (A) and interferon release by ELISA as…

Supplementary Tables S1-S2 and Supplementary Figures S1-S5 from The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Open

Nirmitha I. Herath, Flavien Devun, Marie-Christine Lienafa, Aurélie Herbette, Alban Denys , et al. · 2023

Table S1: Treatment group allocation of mice post intrahepatic grafting; Figure S1: DT01 in combination with single agent chemotherapy; Figure S2: Proportion of apoptotic nuclei in HES sections; Figure S3: Average body weight (g) of mice d…

Sup Figure S3 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Sup Figure S3. Micronuclei frequency but not doubling time nor AsiDNA cell uptake or activation of H2AX phosphorylation, are predictive biomarker for sensitivity to AsiDNA. Spearman correlation between AsiDNa efficiency (AsiDNA EC50, ÂµM),…

Data from The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Open

Nirmitha I. Herath, Flavien Devun, Marie-Christine Lienafa, Aurélie Herbette, Alban Denys , et al. · 2023

Metastatic liver disease from colorectal cancer is a significant clinical problem. This is mainly attributed to nonresectable metastases that frequently display low sensitivities to available chemotherapies and develop drug resistance part…

Sup Figure S1 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Sup Figure S1. AsiDNA Structure and Cell survival in response to AsiDNA treatment. (A) AsiDNA structure: AsiDNA is the clinical form of Dbait, a 64-nucleotide (nt) oligodeoxyribonucleotide consisting of two complementary 32-nt strands, con…

Sup Figure S3 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Sup Figure S3. Micronuclei frequency but not doubling time nor AsiDNA cell uptake or activation of H2AX phosphorylation, are predictive biomarker for sensitivity to AsiDNA. Spearman correlation between AsiDNa efficiency (AsiDNA EC50, ÂµM),…

Supplementary Tables S1-S2 and Supplementary Figures S1-S5 from The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Open

Nirmitha I. Herath, Flavien Devun, Marie-Christine Lienafa, Aurélie Herbette, Alban Denys , et al. · 2023

Table S1: Treatment group allocation of mice post intrahepatic grafting; Figure S1: DT01 in combination with single agent chemotherapy; Figure S2: Proportion of apoptotic nuclei in HES sections; Figure S3: Average body weight (g) of mice d…

Sup Figure S5 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Sup Figure S5. Survival of malignant hematologic and normal human primary immune cells in response to AsiDNA dose escalation in combination with cyclophosphamids (4-HC). (see legend SupFigure-S4)

Sup Figure S4 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Sup Figure S4. Survival of malignant hematologic and normal human primary immune cells in response to AsiDNA dose escalation in combination with Etoposide: Cell survival was determined by MTT assay after four days of treatment. Data are pr…

Sup Figure S2 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Sup Figure S2.AsiDNA does not induce cell cycle modification: Normal and malignant cells were analyzed by flow cytometry after 12, 24 and 48 hours of treatment with 4.8 Ãƒâ€šÃ,âµM AsiDNA. Results are expressed as the mean of the percentage…

Data from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Hematologic malignancies are rare cancers that develop refractory disease upon patient relapse, resulting in decreased life expectancy and quality of life. DNA repair inhibitors are a promising strategy to treat cancer but are limited by t…

sup Figure S7 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Sup Figure S7. Survival of malignant hematologic and normal human primary immune cells in response to AsiDNA dose escalation in combination with vincristine sulfate. (see legend SupFigure-S4)

Sup Figure S4 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Sup Figure S4. Survival of malignant hematologic and normal human primary immune cells in response to AsiDNA dose escalation in combination with Etoposide: Cell survival was determined by MTT assay after four days of treatment. Data are pr…

Sup Figure S6 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Sup Figure S6. Survival of malignant hematologic and normal human primary immune cells in response to AsiDNA dose escalation in combination with irradiations. (see legend SupFigure-S4)

Data from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Hematologic malignancies are rare cancers that develop refractory disease upon patient relapse, resulting in decreased life expectancy and quality of life. DNA repair inhibitors are a promising strategy to treat cancer but are limited by t…

Sup Figure S5 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Sup Figure S5. Survival of malignant hematologic and normal human primary immune cells in response to AsiDNA dose escalation in combination with cyclophosphamids (4-HC). (see legend SupFigure-S4)

Data from The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Open

Nirmitha I. Herath, Flavien Devun, Marie-Christine Lienafa, Aurélie Herbette, Alban Denys , et al. · 2023

Metastatic liver disease from colorectal cancer is a significant clinical problem. This is mainly attributed to nonresectable metastases that frequently display low sensitivities to available chemotherapies and develop drug resistance part…

sup Figure S7 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Sup Figure S7. Survival of malignant hematologic and normal human primary immune cells in response to AsiDNA dose escalation in combination with vincristine sulfate. (see legend SupFigure-S4)

Sup Figure S6 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Sup Figure S6. Survival of malignant hematologic and normal human primary immune cells in response to AsiDNA dose escalation in combination with irradiations. (see legend SupFigure-S4)

Sup Figure S8 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Open

Sylvain Thierry, Wael Jdey, Solana Alculumbre, Vassili Soumelis, Patricia Noguiez‐Hellin , et al. · 2023

Sup Figure S8. Time course analysis of pDC activation by CpG- Dbait. Representative experiments of time course analysis of pDC activation by flow cytometry analysis of cell membrane activation markers (A) and interferon release by ELISA as…

Table S1 from Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Open

Wael Jdey, Sylvain Thierry, Tatiana Popova, Marc‐Henri Stern, Marie Dutreix · 2023

Micronuclei assessement in Breast Cancer patients'' biopsies. MN, Micronuclei; BC, Breast Cancer; C: canalar; L: lobular.

Data from Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors Open

Wael Jdey, Sylvain Thierry, Christophe Russo, Flavien Devun, Muthana Al Abo , et al. · 2023

Purpose: Cancer treatments using tumor defects in DNA repair pathways have shown promising results but are restricted to small subpopulations of patients. The most advanced drugs in this field are PARP inhibitors (PARPi), which trig…

Data from Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Open

Wael Jdey, Sylvain Thierry, Tatiana Popova, Marc‐Henri Stern, Marie Dutreix · 2023

Therapeutic strategies targeting DNA repair pathway defects have been widely explored, but often only benefit small numbers of patients. Here we characterized potential predictive biomarkers for treatment with AsiDNA, a novel first-in-clas…

FigureS2 from AsiDNA Is a Radiosensitizer with no Added Toxicity in Medulloblastoma Pediatric Models Open

Sofia Ferreira, Chloé Foray, Alberto Gatto, Magalie Larcher, Sophie Heinrich , et al. · 2023

Effect of treatments in developing models.

Fetching topic information...